Experimental studies conducted in a mice model of NAFLD demonstrated that chronic administration of monacolin K reduced circulating insulin levels, obesity-related inflammatory markers and liver fat deposits, thus slowing progression of NAFLD to NASH [13]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.